• Skip to main content
  • Skip to footer

Qu Biologics

  • Who We Are
    • Mission and Values
    • Team and Board
  • What We Do
    • Transformational Science
    • SSI Platform
    • SSI Pipeline
    • Publications
  • Current Clinical Trial
    • PERIOP-06 Study
  • News
    • In the Press
  • Investors
  • Careers
  • Contact
Search
Close Search
Publications

Publications

Peer-Reviewed Manuscripts

  • Distinct inactivated bacterial-based immune modulators vary in their therapeutic efficacies for treating disease based on the organ site of pathology.
  • Novel Microbial-Based Immunotherapy Approach for Crohn’s Disease.
  • Immune Stimulation Using a Gut Microbe-Based Immunotherapy Reduces Disease Pathology and Improves Barrier Function in Ulcerative Colitis. 
  • Harnessing innate lung anti-cancer effector functions with a novel bacterial-derived immunotherapy.
  • Attenuating immune pathology using a microbial-based intervention in a mouse model of cigarette smoke-induced lung inflammation.
  • A novel microbe-based treatment that attenuates the inflammatory profile in a mouse model of allergic airway disease.
  • Site-Specific Immunomodulator: A Novel Treatment for Crohn’s Disease.
Logo Light
  • Who We Are
  • What We Do
  • Current Clinical Trial
  • News
  • Investors
  • Careers
  • Contact
  • 4475 Wayburne Drive, Suite 305 Burnaby, B.C., Canada, V5G 4X4
  • 604.734.1450
    info@qubiologics.com

dashicons-facebook-alt
dashicons-twitter
dashicons-linkedin
dashicons-youtube

© 2025 Qu Biologics Inc. All Rights Reserved
| Terms of Use | Privacy Policy